NCCN Guidelines for Breast Cancer Updated; Bevacizumab Recommendation Affirmed

The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Guidelines™ for Breast Cancer to address the use of bevacizumab in metastatic disease. October 18, 2010 FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Breast Cancer to affirm the recommendation regarding the use of bevacizumab (Avastin®, Genentech/Roche) in the treatment of metastatic breast cancer....
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news